2cureX AB (publ) decided to elect Grith Hagel as a new board member. This election a part of a strategic initiative as 2cureX refines its strategy to facilitate the implementation of IndiTreat® testing across individual hospitals. Such a move towards decentralization necessitates an enhancement of the company's expertise in technical and regulatory areas.

Grith Hagel is poised to significantly contribute to the integration and adoption of the IndiTreat® platform within cancer hospitals due to her background and expertise. The Board of Directors hereafter consists of Tonny Bülow-Nielsen, Grith Hagel and Ole Thastrup.